# Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

> **NCT00154388** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 185 (actual)

## Conditions studied

- Life Threatening Diseases

## Interventions

- **DRUG:** Imatinib mesylate

## Key facts

- **NCT ID:** NCT00154388
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-02
- **Primary completion:** 2007-01
- **Final completion:** 2007-01
- **Target enrollment:** 185 (ACTUAL)
- **Last updated:** 2016-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00154388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00154388, "Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00154388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*